PARP Inhibitors in Metastatic Prostate Cancer

by admin_63069 | Nov 20, 2024 | Related Topics

Efficacy, trials, and combination therapies

What’s New

PARP Inhibitors in Metastatic Prostate Cancer
Older Men Increasingly Overtreated for Prostate Cancer
Exercise, Nutrition and Prostate Cancer
Prostate Cancer Treatment Associated With Long-Term Complications
High Decipher Score is Predictive of Docetaxel Benefit in Advanced Prostate Cancer

Disclaimers:

PCSANM provides education, information, and support, not medical advice. Please contact your physician for all your medical concerns. No copyrighted material belonging to others is knowingly used without permission. If any is inadvertently used without permission, please contact our office. Articles are selected from a variety of sources to give as wide a range of content as possible. PCSANM does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.

2533 Virginia St. NE, Suite C Albuquerque, NM 87110

Phone: (505) 254-7784
Toll Free: (800) 278-7678
Fax: (505) 254-7786

Email: pchelp@pcsanm.org

Donate
Contact Us